🔗 Share this article

Ministers and senior MPs have issued warnings that the United Kingdom's series of deals with Washington are "lacking a solid foundation." This follows revelations that a so-called "milestone" deal on medicines, which commits to zero tariffs in exchange for the NHS paying more, lacks any underlying contract beyond limited headline terms outlined by government press releases.

Lacking Legal Footing

The arrangement concerning medicines, hailed as a "landmark" achievement, remains an "broad understanding" without a signed legal text. Critics have noted that the public statements from the UK and US governments describe the deal in sharply different terms. The British version emphasizes securing "zero per cent tariffs" as a singular success, while the American announcement highlights the agreement for the NHS to pay significantly more for new medications.

"The danger exists that the UK government has promised concessions to raise drug prices in return for only a verbal promise from President Trump," commented David Henig, a trade expert. "It is documented he has form for not honouring his word."

Wider Concerns Amidst a Suspended Agreement

Anxieties have been amplified by Washington's action to put on ice the £31bn "tech prosperity deal", which was previously heralded as "a generational step-change" in the bilateral relationship. The US pointed to a lack of progress from the UK on reducing other tariffs as the reason for the pause.

In a separate development, concessions promised for British farmers as part of an May trade agreement have not been formally ratified by the US, despite a fast-approaching January deadline. "Our understanding is that the US has not yet signed off the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Uncertainty Among Officials

In confidential discussions, ministers have voiced worries that the government's US-UK accords are unstable and unpredictable. One minister reportedly said the series of agreements as "built on sand," while another framed the situation as the "new normal" in the transatlantic relationship, marked by "additional layers of volatility and unpredictability."

Layla Moran, a senior MP on the health committee, remarked: "Perhaps most shocking than Trump's temper tantrums is the UK government's naive belief that his administration is a reliable partner. The NHS is too precious to be gambled with."

Official Reassurances and Concrete Outcomes

Ministry sources have downplayed the risk of the US backing out of the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been advocating for the agreement, desiring stability on imports and pricing, making it of tangible value than the paused tech deal.

Officials acknowledge that volatility is part and parcel of dealing with the current US leadership. However, they contend that the UK has achieved real benefits for businesses, such as reduced duties on automobiles compared to other nations. "Our achievement of 25% steel tariffs, which is better than the rate for the rest of the world, is a concrete advantage," one official said.

However, issues have surfaced in implementing the May tariff agreement. Promised access for British beef have yet to be finalized, and the commitment to "remove tariffs on British steel and aluminium" has not been fulfilled, with tariffs staying at 25%.

Looking ahead, the two sides have scheduled to restart talks on the suspended digital agreement in January, following what were described as "very positive" meetings between UK and US officials in Washington.